Jordan Franklin
Research Subjects
Jordan Franklin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adrian F. Hernandez
Duke University School of Medicine, Durham, North Carolina, USA
1 shared publication - Alpaslan Tasdogan
Department of Dermatology, University Hospital Essen & German Cancer Consortium, Partner Site (DKTK) and Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany
1 shared publication - Ashley A. Rowe
Children’s Medical Center Research Institute
1 shared publication - Ashley Solmonson
Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publication - Aundrea K. Westfall
Children’s Medical Center Research Institute
1 shared publication Başak Dogan
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication
Latest Publications
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
l-2-Hydroxyglutarate impairs neuronal differentiation through epigenetic activation of MYC expression
High levels of l- and d-2-hydroxyglutarate (2HG), the reduced forms of α-ketoglutarate (αKG), are implicated in neurodevelopmental disorders and cancer by modulating αKG-dependent dioxygenases involved in histone, DNA, and RNA demethylation. L-2HG dehydrogenase (L2HGDH) deficiency, a rare autosomal recessive inborn error of metabolism associated with systemic L-2HG elevation, causes progressive neurological disability and increased brain tumor risk of unclear mechanism. Using an isogenic, patient-derived induced pluripotent stem cell system, we examined the impact of L2HGDH deficiency on neural progenitor cell (NPC) function and neuronal differentiation. L2HGDH deficiency caused L-2HG accumulation, NPC hyperproliferation, increased clonogenicity, and defective neuronal differentiation in 2D cultures and cortical spheroids. Editing the L2HGDH locus to WT reversed these effects. Inhibiting glutaminase reduced L-2HG levels and induced neuronal differentiation. L-2HG–dependent inhibition of KDM5 histone demethylases led to widespread retention of H3K4me2/3, markers of active gene expression, with prominent enrichment at the MYC locus and elevated MYC expression across multiple neural cell types. Despite broadly altered histone methylation, genetically or pharmacologically normalizing MYC completely restored neuronal differentiation. These data indicated that a primary metabolic disturbance activated MYC to favor self-renewal and suppress neuronal lineage commitment.
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Open Accessl-2-Hydroxyglutarate impairs neuronal differentiation through epigenetic activation of MYC expression
High levels of l- and d-2-hydroxyglutarate (2HG), the reduced forms of α-ketoglutarate (αKG), are implicated in neurodevelopmental disorders and cancer by modulating αKG-dependent dioxygenases involved in histone, DNA, and RNA demethylation. L-2HG dehydrogenase (L2HGDH) deficiency, a rare autosomal recessive inborn error of metabolism associated with systemic L-2HG elevation, causes progressive neurological disability and increased brain tumor risk of unclear mechanism. Using an isogenic, patient-derived induced pluripotent stem cell system, we examined the impact of L2HGDH deficiency on neural progenitor cell (NPC) function and neuronal differentiation. L2HGDH deficiency caused L-2HG accumulation, NPC hyperproliferation, increased clonogenicity, and defective neuronal differentiation in 2D cultures and cortical spheroids. Editing the L2HGDH locus to WT reversed these effects. Inhibiting glutaminase reduced L-2HG levels and induced neuronal differentiation. L-2HG–dependent inhibition of KDM5 histone demethylases led to widespread retention of H3K4me2/3, markers of active gene expression, with prominent enrichment at the MYC locus and elevated MYC expression across multiple neural cell types. Despite broadly altered histone methylation, genetically or pharmacologically normalizing MYC completely restored neuronal differentiation. These data indicated that a primary metabolic disturbance activated MYC to favor self-renewal and suppress neuronal lineage commitment.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e005073
CARS2 Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e005073
CARS2 Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy
- 14 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 507-520
False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis
Purpose Mitigating false negative imaging studies remains an important issue given its association with worse morbidity and mortality in patients with breast cancer. We aimed to identify risk factors that predispose to false negative breast imaging exams. Methods In an IRB-approved, HIPAA compliant retrospective study, we identified all patients who were diagnosed with breast cancer within 365 days of a negative imaging study assessed as BI-RADS 1-3 between January 1, 2014 and January 31, 2020. A matched cohort based on mammographic breast density was created from randomly selected studies with BI-RADS 4-5 designation that yielded breast cancer at pathology within the same time frame. Patient and cancer characteristics, prior personal history of breast cancer and gene mutation status were collected from patient charts. Pearson chi-squared and Student’s t-test on two independent groups with significance at < 0.05 was used for statistical analysis. Results We identified 155 false negative studies of 129 missed cancers and 128 breast density matched true positive cancers. False negative studies were screening mammograms in 57.42% (89/155), diagnostic mammograms in 29.68% (46/155), ultrasounds in 6.45% (10/155) and MRIs in 6.45% (10/155). Rates of personal (41.09% vs. 18.75%, p < 0.001) and family history of breast cancer (68.22% vs. 49.21%, p = 0.002) were higher in the false negative cohort and remained significant when asymptomatic MRI-detected cancers were removed. Conclusion Our findings suggest that supplemental screening may be useful in breast cancer survivors.
- 14 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 507-520
False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis
Purpose Mitigating false negative imaging studies remains an important issue given its association with worse morbidity and mortality in patients with breast cancer. We aimed to identify risk factors that predispose to false negative breast imaging exams. Methods In an IRB-approved, HIPAA compliant retrospective study, we identified all patients who were diagnosed with breast cancer within 365 days of a negative imaging study assessed as BI-RADS 1-3 between January 1, 2014 and January 31, 2020. A matched cohort based on mammographic breast density was created from randomly selected studies with BI-RADS 4-5 designation that yielded breast cancer at pathology within the same time frame. Patient and cancer characteristics, prior personal history of breast cancer and gene mutation status were collected from patient charts. Pearson chi-squared and Student’s t-test on two independent groups with significance at < 0.05 was used for statistical analysis. Results We identified 155 false negative studies of 129 missed cancers and 128 breast density matched true positive cancers. False negative studies were screening mammograms in 57.42% (89/155), diagnostic mammograms in 29.68% (46/155), ultrasounds in 6.45% (10/155) and MRIs in 6.45% (10/155). Rates of personal (41.09% vs. 18.75%, p < 0.001) and family history of breast cancer (68.22% vs. 49.21%, p = 0.002) were higher in the false negative cohort and remained significant when asymptomatic MRI-detected cancers were removed. Conclusion Our findings suggest that supplemental screening may be useful in breast cancer survivors.